Overall verdict
Neutral
6.0/10
1-year performance
+112.84%
Score breakdown
Up 112.8% over 1 year, 97% of the 52-week range.
Strongest: Growth 7.6/10. Weakest: Shareholder return 2.5/10.
18 analysts, target +0.2% vs the price.
BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations.
It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well as rehabilitation services, including physical, speech and occupational therapy and applied behavioral analysis. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
Jon Rousseau
Founded
1974
Employees
23 500
Revenue / employee
549 386 USD
Next earnings
February 25, 2027 (estimated)
Institutional holders
- FMR LLC8.87%
- GEODE CAPITAL MANAGEMENT, LLC2.82%
- Bank of New York Mellon Corp0.85%
- Rest of the register87.45%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
73.75 USD
52-week low
30.64 USD
1-year performance
112.84%
Rising
Year-to-date performance
92.82%
Rising
Drawdown
-1.90%
Near its high
Position in the 52-week range
97% of range
Range: 73.50 USD - 92.00 USD (2 methods agree)
The price implies growth of 10.05% per year; the company grows at -10.00%.
Gross margin 12.5%, net margin 2.0%, ROIC 7.0%, ROE 15.6%.
Net margin
2.04%
Low
Sector 4.74%|S&P 13.40%
Gross margin
12.50%
Low
Return on equity (ROE)
15.57%
Exceptional
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
7.00%
Fair
Free cash flow margin (FCF)
3.21%
Low
Profit-to-cash conversion (FCF conversion)
1.57x
High
Revenue to net income
Growth
7.6/10Revenue up 26.4% over 1 year, 18.3% a year over 5, EPS -20.8% a year over 5.
Revenue (trailing 12 months)
15.3Md USD
Revenue growth (1y)
26.37%
Hyper-growth
Revenue growth (3y)
67.22%
Strong
EPS growth (1y)
78.38%
Hyper-growth
EPS CAGR (5y)
-20.78%
Declining
EPS revisions (3 months)
5.66%
Sharply revised up
Valuation
3.4/10P/E 47.0x, forward P/E 43.0x, EV/EBITDA 23.4x, PEG 0.30. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
47.0x
Expensive
Sector 27.0x|S&P 23.6x
Forward P/E
43.0x
Expensive
EV / EBITDA
23.4x
Expensive
Sector 12.5x|S&P 15.5x
PEG
0.30
Growth unpriced
Sector 0.67|S&P 0.91
Fair value (reverse DCF)
84.00 USD
Undervalued
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
14.4Md USD
Financial strength
3.1/10Cash covers 30.2% of the debt, net debt/EBITDA 4.6x.
Net debt / EBITDA
4.6x
Stretched
Gearing (net debt / equity)
76.00%
Tight
Cash
718M USD
Cash / market cap
4.99%
Tight
Cash / total debt
30.17%
Solid
Interest coverage
3.6x
Tight
Net debt
1.7Md USD
Equity
2.2Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 72.49 USD
- MM2063.90
- MM5061.24
- MM20055.71
- RSI 1469.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.95%
200-day average slope, 3 months
+16.45%
50-day average slope, 1 month
+2.55%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.46 % per day
Volatility change
+26.21%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.68 (7) | 1.92 (16) | 16 054 (17) | 857 (17) | 370 (7) |
| 2027 | 2.12 (7) | 2.43 (17) | 18 421 (18) | 1 007 (17) | 466 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.4Md USD | 47.0x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 112.8 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
